Clincosm LogoSign in Get a demo

Retinal Function in Parkinson's Disease

Sponsor
US Department of Veterans Affairs (U.S. Fed)
Overall Status
Unknown status
CT.gov ID
NCT01010074
Collaborator
(none)
50
Enrollment
1
Location
14
Duration (Months)
3.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Parkinson's disease (PD) is a neurodegenerative disorder characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex arising from the basal ganglia normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high level cognitive dysfunction and subtle language problems. Included in the symptomatology experienced by patients with PD, visual abnormalities are not uncommon. Visual changes among patients with PD appear not only dynamic in nature, but differentially affected based on the course of the disease and, perhaps more importantly, its treatment. Parkinson's disease has significant ramifications not only in observation of irregularities in vision, but how vision interacts with entrainment of the circadian clock. The purpose of this study is to examine the relationship between PD and operation of a unique set of retinal cells known to regulate the circadian clock and sleep-wake cycles in human subjects.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease
    Study Start Date :
    Oct 1, 2009
    Anticipated Primary Completion Date :
    Dec 1, 2010
    Anticipated Study Completion Date :
    Dec 1, 2010

    Outcome Measures

    Primary Outcome Measures

    1. pupillary threshold [one]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 64 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Inclusion Criteria: age 18-64 best corrected visual acuity of 20/25 or better in each eye -

    Exclusion Criteria: evidence of any form of eye disease, inability to understand and sign informed consent.

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hines VA Medical Center Hines Illinois United States 60141

    Sponsors and Collaborators

    • US Department of Veterans Affairs

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01010074
    Other Study ID Numbers:
    • PD001
    First Posted:
    Nov 9, 2009
    Last Update Posted:
    Nov 9, 2009
    Last Verified:
    Nov 1, 2009
    Keywords provided by , ,
    retina, Parkinson's disease, ganglion cell, pupillary
    Additional relevant MeSH terms:
    Parkinson Disease

    Study Results

    No Results Posted as of Nov 9, 2009